Breaking News

Eli Lilly and Co.

May 22, 2008

Eli Lilly and Co. has made changes across its executive leadership structure. "Earlier this year I asked each of our senior leaders to look closely at their respective areas to determine if they were optimally structured to meet the demands of our business and our company goals," said John C. Lechleiter, Ph.D., who assumed the role of Lilly president and chief executive officer on April 1, 2008. "As a result of this thorough review, we are implementing a number of changes that will minimize bureaucracy by reducing the number of layers of management, will speed decision-making by clarifying roles and accountabilities, and will allow us to respond more quickly to critical business needs."
Tim Franson, M.D., vice president of global regulatory affairs, will retire from the company after 22 years of service. Dr. Franson has held roles of increasing responsibility throughout his career at Lilly, including positions in medical (both in the U.S. and in Europe), health economics research and decision sciences, clinical research, and regulatory affairs.  
Alan Breier, M.D., vice president of medical and chief medical officer, has been appointed full professor in the department of psychiatry at the Indiana University School of Medicine after an 11-year career at Lilly. Dr. Breier joined the company in 1997 from the National Institutes of Health (NIH) and has published more than 235 scientific articles in areas related to the cause and treatment of severe mental illnesses. He was also honored by the American Psychiatric Association for excellence in medical student education. Dr. Breier has held a variety of leadership roles at Lilly on the Zyprexa product team as well as in medical, and has served as the chief medical officer since 2003.
The primary change for the company's Lilly Research Laboratories (LRL) structure is the creation of a combined global regulatory, medical and patient safety organization, which will create a single point of accountability for regulatory and medical affairs. Tim Garnett, M.D., currently vice president of global patient safety, will assume the role of vice president and chief medical officer and will lead this new organization.
Jen Stotka, M.D. has been named vice president of global regulatory affairs and Don Therasse, M.D. will assume the role of vice president of global patient safety. Both will report to Dr. Garnett.
Karim Bitar has been named president, European operations. Mr. Bitar has 12 years of experience with Lilly, and has held a variety of international roles, most recently as general manager of Lilly Italy.
Philippe Prufer will assume the role of vice president and area director of European mid-size as well as central and eastern European markets. In addition, the markets of Africa, the Middle East, and the Commonwealth of Independent States (CIS) will be combined with the Asian markets (other than China and Japan) and will be led by Eberhard Ludewigs, who will serve as vice president and area director of this expanded region.
Newt Crenshaw, currently president and general manager of Lilly Japan, will assume the newly-created role of vice president of policy, pricing, reimbursement and access, and international corporate affairs. Mr. Crenshaw will be based in Indianapolis and will report directly to Alex Azar, senior vice president of corporate affairs. Replacing Crenshaw in Japan will be Alfonso (Chito) Zulueta, currently Lilly's area director for Asia.
Enrique Conterno, currently vice president of Lilly's U.S. neuroscience business, will become vice president for health care professional markets. In this role, he will lead all Lilly USA efforts aimed at health care professionals, and he will also have therapeutic responsibility for the neuroscience, diabetes and osteoporosis brands.
Jack Bailey, currently vice president of U.S. sales and marketing, business-to-business, will become vice president for account-based markets, and he will have responsibility for institution-based customers. Mr. Bailey will also have therapeutic responsibility for the oncology, endocrine and cardiovascular brands.
Bryce Carmine, executive vice president of global marketing and sales, has implemented changes to the company's sales and marketing operations. Rich Pilnik, currently vice president and chief marketing officer, has announced his retirement from the company. Mr. Pilnik spent 25 years with the company and has held a variety of sales and marketing positions, including general manager of Lilly Mexico and area director for Latin America and Canada. Mr. Pilnik has twice served as the company's chief marketing officer, from 1998 to 2001 and from 2006 to present. From 2001 to 2006 he served as president of Lilly Europe.
The company's global marketing and international marketing organizations are being consolidated, and Dan Hasler, currently vice president of global brands, will assume the role of vice president of this expanded organization. Nancy Lilly, currently vice president of U.S. sales and marketing for specialty products, is being named to the role of vice president of new product planning and market analytics, responsible for leading new product planning, market research, global pricing and business development.
Transitions for all of the executive leadership and organizational changes will begin immediately, and the new structure will be fully in place by July 1, 2008.

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks